XML 52 R42.htm IDEA: XBRL DOCUMENT v3.20.2

Reportable Segment Information (Tables)

9 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Summary of Financial Information for Each Reportable Segment

The following table presents various financial information for each reportable segment for the three and nine months ended June 30, 2020 and 2019.

	Three months ended								Nine months ended
	June 30								June 30
(In millions - unaudited)	2020				2019				2020				2019
SALES
Life Sciences	$	189			$	190			$	528			$	556
Personal Care & Household		155				158				451				495
Consumer Specialties		344				348				979				1,051
Specialty Additives		135				177				429				494
Performance Adhesives		70				88				229				258
Industrial Specialties		205				265				658				752
Intermediates and Solvents		37				41				102				118
Intersegment sales (a)
Intermediates and Solvents		(12	)			(13	)			(22	)			(37	)
	$	574			$	641			$	1,717			$	1,884
OPERATING INCOME (LOSS)
Life Sciences	$	40			$	32			$	97			$	88
Personal Care & Household		16				17				(309	)			60
Consumer Specialties		56				49				(212	)			148
Specialty Additives		15				19				(137	)			(5	)
Performance Adhesives		13				16				40				42
Industrial Specialties		28				35				(97	)			37
Intermediates and Solvents		7				8				(7	)			20
Unallocated and other		(43	)			(49	)			(87	)			(125	)
	$	48			$	43			$	(403	)		$	80
DEPRECIATION EXPENSE
Life Sciences	$	8			$	8			$	24			$	24
Personal Care & Household		10				10				30				30
Consumer Specialties		18				18				54				54
Specialty Additives		15				15				46				84
Performance Adhesives		4				4				10				11
Industrial Specialties		19				19				56				95
Intermediates and Solvents		4				3				10				8
Unallocated and other		—				—				—				3
	$	41			$	40			$	120			$	160

AMORTIZATION EXPENSE
Life Sciences	$	7			$	7			$	21			$	21
Personal Care & Household		9				10				27				28
Consumer Specialties		16				17				48				49
Specialty Additives		5				5				14				14
Performance Adhesives		—				—				1				1
Industrial Specialties		5				5				15				15
Intermediates and Solvents		—				—				—				1
	$	21			$	22			$	63			$	65
EBITDA (b) (c)
Life Sciences	$	55			$	47			$	142			$	133
Personal Care & Household		35				37				(252	)			118
Consumer Specialties		90				84				(110	)			251
Specialty Additives		35				39				(77	)			93
Performance Adhesives		17				20				51				54
Industrial Specialties		52				59				(26	)			147
Intermediates and Solvents		11				11				3				29
Unallocated and other		(43	)			(49	)			(83	)			(122	)
	$	110			$	105			$	(216	)		$	305
									June 30, 2020				September 30, 2019
TOTAL ASSETS
Life Sciences									$	1,979			$	1,946
Personal Care & Household										979				1,366
Consumer Specialties										2,958				3,312
Specialty Additives										1,642				1,775
Performance Adhesives										595				618
Industrial Specialties										2,237				2,393
Intermediates and Solvents										164				185
Unallocated and other										1,627				1,361
									$	6,986			$	7,251

(a) Intersegment sales from Intermediates and Solvents are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.

(b) Excludes income (loss) from discontinued operations, other net periodic benefit income (expense) and net income (loss) on divestitures. See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.

(c) Includes $39 million of accelerated depreciation for the nine months ended June 30, 2019.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration